All articles by

FDA grants Orphan Drug Designation to Inhibikase’s Risvodetinib in MSA

Risvodetinib is a chronically administered oral drug candidate that targets the underlying biological mechanism of Parkinson’s disease with an intention to halt the disease progression and reverse the functional loss

Sanguina Announces U.S. FDA-Clearance for AnemoCheck Home

AnemoCheck Home is the only FDA-cleared home anemia test with instant results

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

The program is designed to help patients access treatment, providing prescription fulfillment services, insurance benefits investigation, educational support, and help in obtaining financial assistance for qualified patients, among other services

WHO’s advisory group recommends Takeda’s Qdenga vaccine for dengue

The United Nations’ health agency will consider the SAGE’s recommendation and revise its position paper on dengue vaccines to include final guidance on Qdenga’s use in public vaccination campaigns

FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

The updated vaccine addresses currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death

American pharma company Viatris to sell certain businesses for $3.4bn

The drugmaker has received offer for its OTC business, and has agreed to divest its women’s healthcare business, its API business in India, and commercialisation rights in few non-core markets

UK’s MHRA approves Jemperli with chemotherapy in endometrial cancer treatment

GSK’s Jemperli plus chemotherapy is now approved for patients with a tumour abnormality called mismatch repair deficient / microsatellite instability-high by slowing the progression of the disease

Novo Nordisk’s Rivfloza secures FDA nod for adults, children with PH1

The approval was supported by the positive findings from the Phase 2 PHYOX 2 clinical trial and interim data from the ongoing Phase 3 PHYOX 3 extension trial

SGC, HitGen collaborate on DEL technology for drug discovery

HitGen will leverage its DNA-encoded library (DEL) technology platform for the collaboration, specifically the OpenDEL solution, a self-service DEL kit with more than three billion compounds, to screen the under-represented targets selected by SGC

Amicus gets FDA approval for Pombiliti + Opfolda to treat Pompe disease

The FDA has cleared the muscle disorder therapy only for adult LOPD patients whose weight is ≥40kg and who are not improving on their current enzyme replacement therapy